Phase II Trial Using Erbitux + Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Trial Profile

Phase II Trial Using Erbitux + Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2017 Status changed from completed to discontinued.
    • 08 Aug 2016 Status changed from recruiting to completed.
    • 25 Jul 2013 Planned end date changed from 1 Apr 2018 to 1 May 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top